Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients

Joint modeling is increasingly popular for investigating the relationship between longitudinal and time-to-event data. However, numerical complexity often restricts this approach to linear models for the longitudinal part. Here, we use a novel development of the Stochastic-Approximation Expectation Maximization algorithm that allows joint models defined by nonlinear mixed-effect models. In the context of chemotherapy in metastatic prostate cancer, we show that a variety of patterns for the Prostate Specific Antigen (PSA) kinetics can be captured by using a mechanistic model defined by nonlinear ordinary differential equations. The use of a mechanistic model predicts that biological quantities that cannot be observed, such as treatment-sensitive and treatment-resistant cells, may have a larger impact than PSA value on survival. This suggests that mechanistic joint models could constitute a relevant approach to evaluate the efficacy of treatment and to improve the prediction of survival in patients.

[1]  Alan S. Perelson,et al.  Modelling hepatitis C therapy—predicting effects of treatment , 2015, Nature Reviews Gastroenterology &Hepatology.

[2]  Rodolphe Thiébaut,et al.  NIMROD: A program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations , 2013, Comput. Methods Programs Biomed..

[3]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[4]  F. Grima,et al.  Temps de doublement du PSA et son calcul , 2005 .

[5]  D. Commenges,et al.  Joint Modeling of the Clinical Progression and of the Biomarkers' Dynamics Using a Mechanistic Model , 2011, Biometrics.

[6]  Marc Lavielle,et al.  Joint modelling of longitudinal and repeated time-to-event data using nonlinear mixed-effects models and the stochastic approximation expectation–maximization algorithm , 2015 .

[7]  Bradley P Carlin,et al.  Separate and Joint Modeling of Longitudinal and Event Time Data Using Standard Computer Packages , 2004 .

[8]  Rizopoulos Dimitris,et al.  Joint Modeling of Longitudinal and Time-to-Event Data , 2014 .

[9]  Roy S Herbst,et al.  Mode of action of docetaxel - a basis for combination with novel anticancer agents. , 2003, Cancer treatment reviews.

[10]  T. Fojo,et al.  Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. , 2008, The oncologist.

[11]  Wei Liu,et al.  Analysis of Longitudinal and Survival Data: Joint Modeling, Inference Methods, and Issues , 2012 .

[12]  L E Friberg,et al.  A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis , 2014, CPT: pharmacometrics & systems pharmacology.

[13]  Dimitris Rizopoulos,et al.  JM: An R package for the joint modelling of longitudinal and time-to-event data , 2010 .

[14]  Dimitris Rizopoulos,et al.  Joint Models for Longitudinal and Time-to-Event Data: With Applications in R , 2012 .

[15]  France Mentré,et al.  Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose–Response Models , 2012, The AAPS Journal.

[16]  M Tod,et al.  A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer* , 2015, CPT: pharmacometrics & systems pharmacology.

[17]  Marc Lavielle,et al.  Joint modelling of longitudinal and repeated time-to-event data using nonlinear mixed-effects models and the stochastic approximation expectation–maximization algorithm , 2015 .

[18]  France Mentré,et al.  Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. , 2011, Biometrics.

[19]  Cécile Proust-Lima,et al.  Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. , 2008, International journal of radiation oncology, biology, physics.

[20]  Cécile Proust-Lima,et al.  Shared random-effect models for the joint analysis of longitudinal and time-to-event data: application to the prediction of prostate cancer recurrence , 2014 .

[21]  Peter J Diggle,et al.  Joint modelling of repeated measurement and time-to-event data: an introductory tutorial. , 2015, International journal of epidemiology.

[22]  Peihua Qiu,et al.  Model selection and diagnostics for joint modeling of survival and longitudinal data with crossing hazard rate functions , 2014, Statistics in medicine.

[23]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[24]  D. Petrylak.  Therapeutic options in androgen‐independent prostate cancer: building on docetaxel , 2005, BJU international.

[25]  I. Tannock,et al.  Drug resistance in metastatic castration-resistant prostate cancer , 2011, Nature Reviews Clinical Oncology.

[26]  É. Moulines,et al.  Convergence of a stochastic approximation version of the EM algorithm , 1999 .

[27]  Geert Verbeke,et al.  Fully exponential Laplace approximations for the joint modelling of survival and longitudinal data , 2009 .

[28]  France Mentré,et al.  Evaluation of Estimation Methods and Power of Tests of Discrete Covariates in Repeated Time-to-Event Parametric Models: Application to Gaucher Patients Treated by Imiglucerase , 2014, The AAPS Journal.

[29]  France Mentré,et al.  Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches , 2015, The AAPS Journal.

[30]  Dimitris Rizopoulos,et al.  Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time‐to‐Event Data , 2011, Biometrics.